V-Wave's Interatrial Shunt Receives FDA Breakthrough Device Designation for Heart Failure

 

August 15, 2019—V-Wave Ltd., a privately held Israel-based company developing novel implantable interatrial shunt devices, announced that the FDA has granted Breakthrough Device designation for its interatrial shunt for heart failure.

V-Wave's minimally invasive, implanted interatrial shunt is being evaluated in the pivotal RELIEVE-HF investigational device exemption trial. The global, randomized, controlled, double-blinded study. It is enrolling 500 patients who have advanced heart failure with preserved or reduced left ventricular ejection fraction who remain symptomatic despite the use of guideline-directed medical and device therapies.

The V-Wave interatrial shunt system is under clinical investigation and is not available for sale in the United States or other countries, cautioned the company.

In its announcement, the company advised that the FDA's breakthrough device designation is granted to devices that have the potential to offer a more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases. The program aims to provide patients and health care providers with more timely access to medical devices by speeding their development, assessment, and review, including prioritized review all the way through market approval.

The company additionally noted that the Centers for Medicare & Medicaid Services has announced that it is developing a means to expedite reimbursement pathways and provide increased payments for medical devices designated as a breakthrough.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.